Innovation in Digital Pathology Acupath Laboratories has recently partnered with Azer Scientific to introduce the AzerView Digital Pathology scanner in the United States, showcasing their commitment to incorporating advanced imaging technology. This positions them as a forward-thinking provider open to adopting new digital solutions, presenting opportunities to offer innovative imaging equipment and software integrations.

Expanding Diagnostic Offerings The launch of the BioFire FilmArray Gastrointestinal Pathogen Panel indicates a focus on expanding their molecular diagnostic capabilities. Sales teams could leverage this to promote additional test panels, reagents, and lab automation tools that complement their current offerings and cater to their investment in comprehensive pathogen diagnostics.

Strategic Partnerships Acupath’s collaborations with companies like Lumea and Test Today USA demonstrate a strategic approach to integrating digital solutions and supporting COVID-19 testing initiatives. This suggests a market opportunity for digital pathology solutions, mobile testing platforms, and integrated systems that enhance their mobile and remote testing services.

Focus on Clinical Utility The publication of a white paper on the clinical utility of their bladder cancer biomarker underscores their emphasis on research-driven diagnostics and evidence-based products. There is potential to introduce advanced biomarker discovery tools, lab automation, and clinical decision support systems that align with their focus on innovation and accuracy.

Growth in Healthcare Services With a revenue range of 1 million to 10 million and a history of providing critical services like COVID-19 testing, Acupath offers opportunities for sales of laboratory consumables, testing kits, remote reporting platforms, and laboratory management software. Engaging with their growth trajectory could enhance their capabilities and efficiency in expanding service lines.